RE: Investor Webinar3 Mar 2021 08:39
SOH summarised the point about growth pretty well, revenue up over 100%, gross margins up and administrative costs down about 25%. I know many were expecting much faster revenue growth by 100% isn’t exactly shabby. More encouraging were words on product extension at Holland and Barrett.
Exciting upside in Sweetbiotix over medium term.
Skin value will now post TW article be reflected in full in balance sheet.
SOH does deliver on his promises is my take but his approach is to diversify the risk across product line and levels.
I suspect 2021 will be profitable ex Skin fair value changes.
Cenkos as a larger broker may well start to generate new investor interest - the comparison withe other companies in space was encouraging.